Von Willebrand Disease (vWD) Treatment Is Tailored to the Subtype of the Disease

 

Von Willebrand Disease (vWD) Treatment centers around preventing bleeding episodes, normally by using medication. It is just a lifelong bleeding disorder brought on by low levels of protein clots in the blood or a deficiency of von Willebrand factor, which binds a key clotting protein, factor VIII, and platelets in blood vessel walls. The three kinds of Von Willebrand disease are acquired, hereditary, and platelet or pseudo type. The three types of hereditary vWD are type 1 vWD, type 2 vWD, and type 3 vWD. Platelet type vWD can be an inherited condition.

It might develop later in life, but in rare cases, it's often inherited. Symptoms may include excessive bleeding from the cut, increased menstrual flow, bleeding from the gums, and recurrent and prolonged nosebleeds. Desmopressin, an antidiuretic hormone, is just a common medication employed for the Von Willebrand disease treatment. It triggers the release of Willebrand factor to the plasma and can increase factor VIII levels. Moreover, several major private sector and government organizations are forging strategic alliances to improve the efficacy and success rate of existing, in addition to upcoming treatments.

Moreover, research and development activities are expected to improve the entire possibility of the von Willebrand disease treatment, and pave the way for new therapies and diagnostics frameworks. Currently, new therapies address the primary deficiency of vWD. Extensive research is underway to judge the efficacy of new treatments in various clinical situations. The demand for Von Willebrand disease treatment is increasing with the increasing demand for progressive treatment methods, an increase in patient assistance programs, and increasing adoption of new technologies, especially in North America.

For instance, Von Willebrand disease is the most typical bleeding disorder, affecting up to 1% of the U.S. population, based on the National Hemophilia Foundation.